RxDoctor Payments Data

Edward Vecchione, DO

Internal Medicine · Nutley, NJNPI 1760440929

Payments from drug & device makers

$10,338in general payments, 2019–2025

Across 776 payments — averaging $13.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$710
  • Amarin Pharma, Inc.$680
  • Lilly USA, LLC$653
  • AbbVie$580
  • plus $5K from 52 others

What the payments were for

  • Food & beverage$10,289100%
  • Education$490%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,338 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$298,696
Medicare patients
473
Services billed
5,605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin183$189,968
OzempicSemaglutide108$145,069
EliquisApixaban106$80,022
JanuviaSitagliptin Phosphate97$67,302
FarxigaDapagliflozin Propanediol60$60,556
RybelsusSemaglutide21$28,547
MounjaroTirzepatide23$23,591
VascepaIcosapent Ethyl42$20,837
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog33$18,265
Xultophy 100-3.6Insulin Degludec/Liraglutide14$17,552
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$17,438
TrulicityDulaglutide14$15,205
XareltoRivaroxaban19$13,621
LinzessLinaclotide21$13,493
Icosapent Ethyl19$11,473

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6$1,377$191,167143 claims
Boehringer IngelheimJardiance$710$189,968183 claims
MerckJanuvia, Janumet, Janumet Xr$369$85,007120 claims
PfizerEliquis$473$80,022106 claims
AstraZenecaFarxiga$1,278$60,55660 claims
Lilly USA, LLCMounjaro, Trulicity$653$38,79637 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$280$25,85146 claims
AbbVieLinzess, Synthroid$580$15,46347 claims
Johnson & JohnsonXarelto$112$13,62119 claims
NovartisEntresto$226$11,44317 claims
Kowa Pharmaceuticals America, Inc.Bystolic$324$5,53914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Nutley

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →